- TRADE NAME: Ongentys (Neurocrine Biosciences)
- INDICATIONS: Adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. (Given concomitantly with levodopa/carbidopa).
- CLASS: Catechol-O-methyl transferase inhibitor
- HALF-LIFE: 1–2 hours
- FDA APPROVAL DATE: 04/24/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Isocarboxazid, Phenelzine, Tranylcypromine - PREGNANCY: No adequate data on the developmental risk associated with use in pregnant women.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
